Vical Says U.S. Navy Advances Dengue DNA Vaccine Using Its Vaxfectin Adjuvant

As per a prior Collaborative Research and Development Agreement with Vical, NMRC developed a tetravalent DNA vaccine containing genes encoding the pre-membrane and envelope proteins for all four serotypes of dengue virus, and formulated with Vical’s Vaxfectin adjuvant. Both Vaxfectin-formulated and unformulated vaccines are now being evaluated in Phase 1 human testing.

via Vical Says U.S. Navy Advances Dengue DNA Vaccine Using Its Vaxfectin Adjuvant.

Advertisements


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s